Confronto
Goserelin vs. Leuprorelin
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
65807-02-5
53714-56-0
Peso molecolare
1269.43 g/mol
1209.4 g/mol
Emivita
4.2 h
3 h
Sequenza
pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Azgly-NH2Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEtMeccanismo d'azione
Goserelin
As a GnRH agonist, goserelin binds to the GnRH receptors of the pituitary gland. Initial stimulation transiently raises luteinizing hormone (LH) and follicle-stimulating hormone (FSH). With continuous receptor occupancy, however, the receptors become desensitized and down-regulated, which reduces LH and FSH secretion and consequently the production of testosterone or estrogen. This mechanistic relationship is documented in the pharmacological literature.
Leuprorelin
Leuprorelin is a GnRH-receptor agonist. After binding to pituitary GnRH receptors, it first causes a transient surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release — the so-called flare. With continuous, non-pulsatile exposure the receptors are downregulated and desensitized, suppressing gonadotropin secretion and consequently lowering sex steroids (testosterone or estradiol) to low levels. This mechanism underlies the literature-described use in hormone-dependent conditions.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
4
4
di cui sull'uomo
4
4
Effetti registrati
3
4
Contraddizioni aperte
1
1
Eventi avversi documentati
2
3
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Goserelin and Leuprorelin?
- Goserelin is classified as "Ricerca (altro)", while Leuprorelin is classified as "Ricerca (altro)". Goserelin: Goserelin is a synthetic decapeptide and an agonist of gonadotropin-releasing hormone (GnRH). The medical literature describes it as a hormonal agent that suppresses the release of sex hormones through sustained receptor stimulation. Regulatory-approved indications include prostate cancer, advanced breast cancer, endometriosis, and endometrial thinning, among others. Leuprorelin: Leuprorelin (also leuprolide) is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH). It is an approved prescription medicine in several jurisdictions, including for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Goserelin or Leuprorelin?
- The highest available evidence level is "RCT sull'uomo" for Goserelin and "RCT sull'uomo" for Leuprorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Goserelin and Leuprorelin in Germany and the United States?
- Germania: Goserelin — Su prescrizione, Leuprorelin — Su prescrizione. Stati Uniti: Goserelin — Su prescrizione, Leuprorelin — Su prescrizione. These are factual summaries with source and review date on the individual pages.